|1.||Tuttle, Katherine R: 7 articles (04/2015 - 04/2005)|
|2.||McGill, Janet B: 5 articles (04/2015 - 11/2005)|
|3.||Anderson, Pamela W: 5 articles (04/2015 - 11/2005)|
|4.||Sheetz, Matthew J: 5 articles (11/2011 - 12/2006)|
|5.||Aiello, Lloyd Paul: 5 articles (11/2011 - 10/2005)|
|6.||Kelly, Darren J: 5 articles (06/2009 - 08/2005)|
|7.||Gilbert, Richard E: 5 articles (06/2009 - 08/2005)|
|8.||Bastyr, Edward J: 4 articles (04/2015 - 08/2005)|
|9.||Davis, Matthew D: 4 articles (11/2011 - 12/2006)|
|10.||Zhang, Yuan: 4 articles (06/2009 - 08/2005)|
|1.||Diabetic Retinopathy (Retinopathy, Diabetic)
01/01/2016 - "Although initial studies have indicated that the treatment of diabetic patients with ruboxistaurin, a specific inhibitor of PKCβ, may reduce visual loss in patients with diabetic retinopathy, the overall benefit seems to be small. "
11/13/2008 - "Based on secondary analyses of clinical trials in patients with diabetic retinopathy or neuropathy, ruboxistaurin appears safe and may also prevent onset of DKD. "
01/01/2008 - "Data are from a randomized, placebo-controlled trial of ruboxistaurin for vision loss in patients with diabetic retinopathy. "
01/01/2007 - "This phase III, randomised, double-blind, multidose study in 252 patients with type 1 and type 2 diabetes receiving ruboxistaurin or placebo for 3-4 years evaluated the safety of the agent and its effect on progression of diabetic retinopathy, moderate vision loss and sustained moderate vision loss. "
01/01/2007 - "Previously, results of the PKC-Diabetic Retinopathy Study (PKC-DRS) showed that ruboxistaurin at a dose of 32 mg/day has potential to reduce the risk of moderate vision loss especially in patients with diabetic macular oedema. "
12/01/2010 - "Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema."
01/01/2009 - "Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema."
10/01/2005 - "Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema."
12/01/2006 - "Initial laser treatment for macular edema was 26% less frequent in eyes of ruboxistaurin-treated patients (P = 0.008). "
12/01/2006 - "When clinically significant macular edema was >100 microm from the center of the macula at baseline, ruboxistaurin treatment was associated with less frequent progression of edema to within 100 microm (68% vs. 50%, P = 0.003). "
04/01/2009 - "Significant reduction in atherosclerosis of approximately 2-fold was observed in apoE(-/-) mice fed ruboxistaurin chow (PKCbeta inhibitor) vs. vehicle. "
11/01/2007 - "The aim of this in vitro study was to investigate the effect of ruboxistaurin on glucose-induced adhesion of monocytes to endothelial cells, representing one of the first pivotal steps in the course of atherogenesis. "
|4.||Low Vision (Subnormal Vision)
|1.||protein kinase C beta
|2.||Protein Kinase C
|4.||Apolipoproteins E (ApoE)
|9.||Transforming Growth Factor beta (TGF-beta)